Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
Reintroduction of the Cyclin A2 gene enables adult human cardiomyocytes to divide, producing functional daughter cells and promoting heart repair. The therapy uses a replication-deficient adenoviral ...
Remibrutinib showed rapid and sustained efficacy in CSU, with significant symptom reduction by week 2, maintained over 52 weeks. The pooled analysis of REMIX-1 and REMIX-2 trials highlighted ...
Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over ...
Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with ...
Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect ...
Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to ...
Panelists discuss how increasing utilization management oversight affects physician autonomy and the shared decision-making ...
Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align ...
Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on ...
Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results